![Infant Bacterial Therapeutics AB (publ) logo](/logos/IBT-B.ST.webp)
Infant Bacterial Therapeutics AB (publ)
SSE:IBT-B.ST
Overview | Financials
Company Name | Infant Bacterial Therapeutics AB (publ) |
Symbol | IBT-B.ST |
Currency | SEK |
Price | 93.4 |
Market Cap | 1,215,890,540 |
Dividend Yield | 0% |
52-week-range | 41.3 - 106.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Staffan Stromberg Ph.D. |
Website | https://www.ibtherapeutics.com |
An error occurred while fetching data.
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD